Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients.
Palmerini E, Jones RL, Setola E, Picci P, Marchesi E, Luksch R, Grignani G, Cesari M, Longhi A, Abate ME, Paioli A, Szucs Z, D'ambrosio L, Scotlandi K, Fagioli F, Asaftei S, Ferrari S. Palmerini E, et al. Among authors: marchesi e. Acta Oncol. 2018 Jul;57(7):958-964. doi: 10.1080/0284186X.2018.1449250. Epub 2018 Mar 13. Acta Oncol. 2018. PMID: 29533113 Free article.
Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2).
Palmerini E, Meazza C, Tamburini A, Bisogno G, Ferraresi V, Asaftei SD, Milano GM, Coccoli L, Manzitti C, Luksch R, Serra M, Gambarotti M, Donati DM, Scotlandi K, Bertulli R, Favre C, Longhi A, Abate ME, Perrotta S, Mascarin M, D'Angelo P, Cesari M, Staals EL, Marchesi E, Carretta E, Ibrahim T, Casali PG, Picci P, Fagioli F, Ferrari S. Palmerini E, et al. Among authors: marchesi e. Cancer. 2022 May 15;128(10):1958-1966. doi: 10.1002/cncr.34131. Epub 2022 Feb 24. Cancer. 2022. PMID: 35201621 Free PMC article. Clinical Trial.
Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
Palmerini E, Chawla NS, Ferrari S, Sudan M, Picci P, Marchesi E, Leopardi MP, Syed I, Sankhala KK, Parthasarathy P, Mendanha WE, Pierini M, Paioli A, Chawla SP. Palmerini E, et al. Among authors: marchesi e. Eur J Cancer. 2017 May;76:118-124. doi: 10.1016/j.ejca.2017.01.028. Epub 2017 Mar 17. Eur J Cancer. 2017. PMID: 28324746
Primary angiosarcoma of bone: a retrospective analysis of 60 patients from 2 institutions.
Palmerini E, Maki RG, Staals EL, Alberghini M, Antonescu CR, Ferrari C, Ruggieri P, Mavrogenis A, Bertoni F, Cesari M, Paioli A, Marchesi E, Picci P, Ferrari S. Palmerini E, et al. Among authors: marchesi e. Am J Clin Oncol. 2014 Dec;37(6):528-34. doi: 10.1097/COC.0b013e31827defa1. Am J Clin Oncol. 2014. PMID: 23466575 Free PMC article.
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
Grignani G, Palmerini E, Ferraresi V, D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y, Sangiolo D, Marchesi E, Capozzi F, Biagini R, Gambarotti M, Fagioli F, Casali PG, Picci P, Ferrari S, Aglietta M; Italian Sarcoma Group. Grignani G, et al. Among authors: marchesi e. Lancet Oncol. 2015 Jan;16(1):98-107. doi: 10.1016/S1470-2045(14)71136-2. Epub 2014 Dec 11. Lancet Oncol. 2015. PMID: 25498219 Free article. Clinical Trial.
The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.
Palmerini E, Colangeli M, Nanni C, Fanti S, Marchesi E, Paioli A, Picci P, Cambioli S, Donati D, Cevolani L, De Paolis M, Gambarotti M, Ferrari S. Palmerini E, et al. Among authors: marchesi e. Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):215-223. doi: 10.1007/s00259-016-3509-z. Epub 2016 Sep 20. Eur J Nucl Med Mol Imaging. 2017. PMID: 27645694 Free PMC article. Clinical Trial.
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Basso U, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Palmerini E, De Sanctis R, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG. Gronchi A, et al. Among authors: marchesi e. Lancet Oncol. 2017 Jun;18(6):812-822. doi: 10.1016/S1470-2045(17)30334-0. Epub 2017 May 9. Lancet Oncol. 2017. PMID: 28499583 Clinical Trial.
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Grignani G, D'Ambrosio L, Pignochino Y, Palmerini E, Zucchetti M, Boccone P, Aliberti S, Stacchiotti S, Bertulli R, Piana R, Miano S, Tolomeo F, Chiabotto G, Sangiolo D, Pisacane A, Dei Tos AP, Novara L, Bartolini A, Marchesi E, D'Incalci M, Bardelli A, Picci P, Ferrari S, Aglietta M. Grignani G, et al. Among authors: marchesi e. Lancet Oncol. 2018 Oct;19(10):1360-1371. doi: 10.1016/S1470-2045(18)30438-8. Epub 2018 Sep 11. Lancet Oncol. 2018. PMID: 30217671 Free article. Clinical Trial.
175 results